Trial · NCT00958282
Treatment of Cocaine Dependence With Lisdexamfetamine
NCT00958282, Phase 2, Completed, University of Minnesota; results first posted 2015-09-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Cocaine Dependence With Lisdexamfetamine. Trials, record NCT00958282. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00958282
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Cocaine Dependence With Lisdexamfetamine
- NCT number
- NCT00958282
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 43 participants, actual
- Lead sponsor
- University of Minnesota
- Conditions
- Cocaine Dependence
- Interventions
- lisdexamfetamine/Behavior Therapy, placebo
- First posted
- 2009-08-13
- Last updated
- 2015-09-17
- Results first posted
- 2015-09-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cocaine-positive Urine Results | 14 Weeks | At each visit, subjects provided urine samples, which were analyzed for benzoylecgonine (BE; a cocaine metabolite). BE was assessed semi-quantitatively using the PROFILE® -V MEDTOXScan® Drugs of Abuse Test System, with cocaine positive tests equaling or exceeding 150 ng/mL. |
| Secondary | Drug Craving | 14 Weeks | On a weekly basis, patients completed measures of cocaine craving using the Minnesota Cocaine Craving Scale. The Minnesota Cocaine Craving Scale is a self report questionnaire and ranges from 0 to 100, 0 being "very little" to 100 being "very much". |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cocaine-positive Urine Results | 14 Weeks | percentage of BE urine tests | MEAN | |
| SECONDARY | Drug Craving | 14 Weeks | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cocaine-positive Urine Results | Lisdexamfetamine | 86.5 | Standard Deviation .5 | percentage of BE urine tests | |
| Cocaine-positive Urine Results | Placebo | 92.4 | Standard Deviation .5 | percentage of BE urine tests | |
| Drug Craving | Lisdexamfetamine | 17.5 | Standard Error 3.30 | units on a scale | |
| Drug Craving | Placebo | 28.7 | Standard Error 3.21 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Lisdexamfetamine | 22 | |
| Overall Study | STARTED | Placebo | 21 | |
| Overall Study | COMPLETED | Lisdexamfetamine | 12 | |
| Overall Study | COMPLETED | Placebo | 15 | |
| Overall Study | NOT COMPLETED | Lisdexamfetamine | 10 | |
| Overall Study | NOT COMPLETED | Placebo | 6 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Angina | Cardiac disorders | Lisdexamfetamine/Behavior Therapy | 1 | 22 | 1 |
| serious | Angina | Cardiac disorders | Placebo | 0 | 21 | 0 |
| serious | Psychosis | Psychiatric disorders | Lisdexamfetamine/Behavior Therapy | 0 | 22 | 0 |
| serious | Psychosis | Psychiatric disorders | Placebo | 1 | 21 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Lisdexamfetamine/Behavior Therapy | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Lisdexamfetamine/Behavior Therapy | 0 | 22 |
| Total, other adverse events | Placebo | 0 | 21 |
| Total, serious adverse events | Lisdexamfetamine/Behavior Therapy | 1 | 22 |
| Total, serious adverse events | Placebo | 1 | 21 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Lisdexamfetamine/Behavior Therapy vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00958282
GET https://conductscience.org/api/trials/v1/NCT00958282/registered